 | |
| Clinical data | |
|---|---|
| Trade names | Ecclock, Sofdra, others |
| Other names | BBI-4000, BBI 4000 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a624052 |
| License data | |
| Routes of administration | Topical |
| Drug class | Anticholinergic |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C22H32BrNO5 |
| Molar mass | 470.404 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Sofpironium bromide, sold under the brand namesEcclock andSofdra among others, is amedication used to treathyperhidrosis (excessive sweating).[1] Sofpironium bromide is ananticholinergic agent that is applied to the skin.[1]
It was approved for medical use in Japan in 2020,[2] and in the United States in June 2024.[1][3][4][5]
Sofpironium bromide isindicated for the treatment of primary axillary hyperhidrosis.[1]
The pharmacodynamics of sofpironium bromide are unknown.[1]
It was approved for medical use in Japan in November 2020,[6] and in the United States in June 2024.[1][7]
Sofpironium bromide is theinternational nonproprietary name.[8]
It is sold under the brand name Ecclock in Japan and under the brand name Sofdra in the US.
